TP53 and medulloblastoma: Here we present first evidence that Vandetanib has profound cytotoxic activity in pediatric medulloblastoma cell lines derived from high-risk SHH-TP53-mutated and MYC-amplified Non-WNT/Non-SHH medulloblastoma [19–25].